Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fat graft may keep Dupuytren's disease from returning after surgery

NCT ID NCT05067764

Disease control Sponsor: Elsan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

Dupuytren's disease causes fingers to bend inward, making hand use difficult. This study compares standard surgery (aponeurectomy) alone versus surgery plus a fat graft taken from the patient's arm. Researchers will track 172 adults for 2 years to see if the fat graft reduces the chance of the disease coming back.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
adipose tissue (fat) graft
What this could lead to
If it works, this could offer a simple way to reduce the chance of Dupuytren's coming back after surgery, helping people keep hand function longer.
What could go wrong
This is a relatively small, early-stage trial. The fat graft may not lower recurrence rates, and there are risks like infection or graft failure. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 172 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Carrier of Tubiana stage II-IV Dupuytren's disease on at least one or more rays, not previously operated * Indication of a surgery by aponeurectomy * Skin pinch of the posterior aspect of the arm of more than 1cm * Affiliation to a social security system * Patient informed of the study and having given informed consent Exclusion Criteria: * Previous surgery of any kind for Dupuytren's disease * Involvement on the thumb only * Need for a total skin graft or a pedicle flap on all the rays to be treated * Active autoimmune disease * Previous treatment with collagenase * Pregnant and breastfeeding women * Patient under legal protection * Contraindications to MRI (criteria applicable only for patients from the coordinating center, not applicable for other centers)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dupuytren's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

palmar fibromatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dupuytren's disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institut Aquitain de la Main

    RECRUITING

    Pessac, 33600, France

  • Santé Atlantique ELSAN

    RECRUITING

    Saint-Herblain, 44800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.